---
document_datetime: 2025-10-09 15:30:17
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/emgality-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: emgality-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5177183
conversion_datetime: 2025-12-28 02:00:36.387991
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Emgality

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc.Article61(3)-Accepted | 09/10/2025                          |                                          | PL                              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000303559                      | Update of the package leaflet with revised contactdetailsoflocalrepresentative and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives inline with the QRD template v10.4.                                                                                                                                                                                                                                                               |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation typeIA/ EMA/VR/0000295225   | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finishedproduct-B.II.b.5.cDeletion of a non-significant in-process test-Refused                                                                                                                                                                                                                                                                                                         | 09/09/2025 | N/A |
| Variation type IB / EMA/VR/0000267327 | C.1.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,includingtherisk management plan - C.I.11.z Change in due dateforcategory1,2or3studiesinthe RMPand/orAnnexII-Accepted C.I.11.z- to request a deadline extension of category 3 study Study I5Q-MC-B003 (B003) from'Q42025'to'Q42027'to fulfill MEA 2.2 request. In addition, the MAH took the opportunity to update the wording on study progress reports in theEU RMP. | 27/05/2025 | N/A |